论文部分内容阅读
乙型肝炎病毒(HBV)感染所致的失代偿性肝硬化预后差。因干扰素常有致死性副作用,故不宜应用于失代偿性肝硬化患者。拉米夫定是口服的核苷类似物,具有强烈抑制HBV复制的作用,对慢性乙型肝炎患者有益。本文报告1例晚期乙型肝炎肝硬化患者,应用拉米夫定治疗后肝脏迅速再生,并伴随临床状态和肝功能显著改善。 病例 男,47岁,患Child C级失代偿性肝硬化。血清HBsAg和HBeAg均阳性,HBV DNA9.8pg/mL,丙型肝炎和丁型肝炎病毒血清学标志均阴性。给予口服拉米夫定(150mg/d)治疗。治疗前,患者肝脏高度萎缩,有功能的肝脏体积仅为913mL[通过放射标记肝脏单光子发
Poor prognosis of decompensated cirrhosis due to Hepatitis B virus (HBV) infection. Interferon often fatal side effects, it should not be used in patients with decompensated cirrhosis. Lamivudine is an oral nucleoside analog that has a strong inhibitory effect on HBV replication and is beneficial for patients with chronic hepatitis B. This article reports a case of advanced hepatitis B cirrhosis patients, the application of lamivudine rapid liver regeneration, and with the clinical status and liver function improved significantly. Case Male, 47 years old with Child-C, decompensated cirrhosis. Serum HBsAg and HBeAg were positive, HBV DNA 9.8pg / mL, hepatitis C and hepatitis D virus serological markers were negative. Oral Lamivudine (150 mg / d) was given. Before treatment, the patient’s liver atrophy, functional liver volume was only 913mL [by radio-labeled liver single photon